Analysis of the FAERS database shows that the real-world abuse potential of the DORA class is very low and markedly less than those seen for other scheduled and non-scheduled insomnia therapies Allschwil, Switzerland – September 8, 2025Idorsia Ltd (SIX: IDIA) presented real-world data from the FDA Adverse Event Reporting System (FAERS) at the World Sleep 2025, evaluating abuse-related adverse events for dual orexin receptor antagonists (DORAs) in comparison to other insomnia therapies. View the poster. Inso ...